Aminoglycoside dosages and nephrotoxicity: quantitative relationships.
OBJECTIVE
To develop a model that relates the probability of occurrence of nephrotoxicity to the cumulative area under the curve (AUC) of amikacin serum concentration.


METHODS
This was a retrospective study of two groups of patients in whom nephrotoxicity was observed after administration of amikacin. The first group consisted of patients treated with once-daily administration (ODA) [n = 13]. The second group consisted of patients treated with twice-daily administration (TDA) [n = 22].


METHODS
The probability of nephrotoxicity occurrence.


RESULTS
The model is a powerful tool to represent and describe the influence of the dosage regimen on aminoglycoside nephrotoxicity. The onset of nephrotoxicity is delayed in the ODA group (p = 0.01) for the same total daily dose among the two groups. The cumulative serum AUC values at onset of nephrotoxicity were greater for the ODA group (p = 0.029). In addition, for the same probability of nephrotoxicity occurrence (50%), the cumulative AUC for the ODA dosage regimen is 2 613 mg. h/L versus only 1 521 mg. h/L for the TDA dosage regimen. The difference in nephrotoxicity between ODA and TDA is greatest for a cumulative AUC of 2 495 mg. h/L, which corresponds to standard therapy with amikacin 900 mg/day during a 7-day period, i.e. 15 mg/kg/day for a 60kg patient with normal renal function (initial creatinine clearance >80 mL/min). For an AUC above 2 495 mg. h/L, the difference in nephrotoxicity decreases slowly to zero. This result means that ODA is especially justified when the treatment is administered over a short duration, i.e. less than 7 days.


CONCLUSIONS
The utility of selecting ODA in order to obtain less nephrotoxicity in comparison with TDA is therefore not established when the treatment is prolonged. In clinical use, the choice of the dosage regimen is not clear-cut, and both expected efficacy and expected toxicity must be taken into account in order to obtain an overall optimisation of each patient's therapy.
UMR CNRS 5558-ADCAPT Service Pharmaceutique, Hôpital Antoine Charial, Francheville, France.
Florent
F
Rougier
Michel
M
Ducher
Michel
M
Maurin
Stéphane
S
Corvaisier
Daniel
D
Claude
Roger
R
Jelliffe
Pascal
P
Maire
D000583:Amikacin / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood; D019540:Area Under Curve; D003404:Creatinine / Q000097:blood; D004334:Drug Administration Schedule; D006801:Humans; D007674:Kidney Diseases / Q000097:blood* / Q000139:chemically induced; D012189:Retrospective Studies
D000900:Anti-Bacterial Agents; D000583:Amikacin; D003404:Creatinine